Breast Cancer Index and Prediction of Benefit from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) Trial

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2019 Sep 11

PMID 31504126

Citations 69

Authors

J M S Bartlett

D C Sgroi

K Treuner

Y Zhang

I Ahmed

T Piper

R Salunga

E F Brachtel

S J Pirrie

C A Schnabel

D W Rea

Affiliations

Soon will be listed here.

Abstract

Background: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therapy. Breast cancer index (BCI) [HOXB13/IL17BR ratio (H/I)] was evaluated for its ability to predict benefit from extended endocrine therapy in patients previously randomized in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.

Patients And Methods: Trans-aTTom is a multi-institutional, prospective-retrospective study in patients with available formalin-fixed paraffin-embedded primary tumor blocks. BCI testing and central determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunohistochemistry were carried out blinded to clinical outcome. Survival endpoints were evaluated using Kaplan-Meier analysis and Cox regression with recurrence-free interval (RFI) as the primary endpoint. Interaction between extended endocrine therapy and BCI (H/I) was assessed using the likelihood ratio test.

Results: Of 583 HR+, N+ patients analyzed, 49% classified as BCI (H/I)-High derived a significant benefit from 10 versus 5 years of tamoxifen treatment [hazard ratio (HR): 0.35; 95% confidence interval (CI) 0.15-0.86; 10.2% absolute risk reduction based on RFI, P = 0.027]. BCI (H/I)-low patients showed no significant benefit from extended endocrine therapy (HR: 1.07; 95% CI 0.69-1.65; -0.2% absolute risk reduction; P = 0.768). Continuous BCI (H/I) levels predicted the magnitude of benefit from extended tamoxifen, whereas centralized ER and PR did not. Interaction between extended tamoxifen treatment and BCI (H/I) was statistically significant (P = 0.012), adjusting for clinicopathological factors.

Conclusion: BCI by high H/I expression was predictive of endocrine response and identified a subset of HR+, N+ patients with significant benefit from 10 versus 5 years of tamoxifen therapy. These data provide further validation, consistent with previous MA.17 data, establishing level 1B evidence for BCI as a predictive biomarker of benefit from extended endocrine therapy.

Trial Registration: ISRCTN17222211; NCT00003678.

Citing Articles

HOXB13 in cancer development: molecular mechanisms and clinical implications.

Zhang J, Li Y, Peng B, Yang X, Chen M, Li Y Front Med. 2025; .

PMID: 40067581 DOI: 10.1007/s11684-024-1119-x.

CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer.

Xue C, Yang W, Hu A, He C, Liao H, Chen M BMC Cancer. 2025; 25(1):410.

PMID: 40050768 PMC: 11887348. DOI: 10.1186/s12885-025-13791-z.

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C Breast. 2025; 80:104415.

PMID: 39985843 PMC: 11904565. DOI: 10.1016/j.breast.2025.104415.

Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.

Wu Y, Liu Y, Wu H, Tong M, Du L, Ren S Int J Nanomedicine. 2025; 20:1425-1442.

PMID: 39925678 PMC: 11804227. DOI: 10.2147/IJN.S504363.

ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.

Mitsiades I, Onozato M, Iafrate A, Hicks D, Gulhan D, Sgroi D Breast Cancer Res. 2024; 26(1):185.

PMID: 39695741 PMC: 11657829. DOI: 10.1186/s13058-024-01943-1.

References

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C . Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):545-553. PMC: 5885222. DOI: 10.1001/jamaoncol.2017.5524. View

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

Zhang Y, Schnabel C, Schroeder B, Jerevall P, Jankowitz R, Fornander T . Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013; 19(15):4196-205. DOI: 10.1158/1078-0432.CCR-13-0804. View

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P . 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017; 377(19):1836-1846. PMC: 5734609. DOI: 10.1056/NEJMoa1701830. View

Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97(17):1262-71. DOI: 10.1093/jnci/dji250. View

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C . Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008; 26(7):1059-65. DOI: 10.1200/JCO.2007.12.9437. View

Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E . Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017; 75:284-298. DOI: 10.1016/j.ejca.2017.01.017. View

Regan M, Pagani O, Francis P, Fleming G, Walley B, Kammler R . Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015; 154(2):275-86. PMC: 4749471. DOI: 10.1007/s10549-015-3612-z. View

Mamounas E, Jeong J, Wickerham D, Smith R, Ganz P, Land S . Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008; 26(12):1965-71. DOI: 10.1200/JCO.2007.14.0228. View

10.

Francis P, Regan M, Fleming G, Lang I, Ciruelos E, Bellet M . Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 372(5):436-46. PMC: 4341825. DOI: 10.1056/NEJMoa1412379. View

11.

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

12.

Mamounas E, Bandos H, Lembersky B, Jeong J, Geyer Jr C, Rastogi P . Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 20(1):88-99. PMC: 6691732. DOI: 10.1016/S1470-2045(18)30621-1. View

13.

Pagani O, Regan M, Walley B, Fleming G, Colleoni M, Lang I . Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2):107-18. PMC: 4175521. DOI: 10.1056/NEJMoa1404037. View

14.

Simon R, Paik S, Hayes D . Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101(21):1446-52. PMC: 2782246. DOI: 10.1093/jnci/djp335. View

15.

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379(2):111-121. PMC: 6172658. DOI: 10.1056/NEJMoa1804710. View

16.

Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 37(5):423-438. DOI: 10.1200/JCO.18.01160. View

17.

Harris L, Ismaila N, McShane L, Andre F, Collyar D, Gonzalez-Angulo A . Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(10):1134-50. PMC: 4933134. DOI: 10.1200/JCO.2015.65.2289. View

18.

Loi S, Fraser Symmans W, Bartlett J, Fumagalli D, Veer L, Forbes J . Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol. 2011; 12(12):1162-8. DOI: 10.1016/S1470-2045(11)70117-6. View

19.

Mehta C, Pocock S . Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med. 2011; 30(28):3267-84. DOI: 10.1002/sim.4102. View

20.

Sgroi D, Sestak I, Cuzick J, Zhang Y, Schnabel C, Schroeder B . Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013; 14(11):1067-1076. PMC: 3918681. DOI: 10.1016/S1470-2045(13)70387-5. View